Pharmaceutical Executive, Dec 1, 2011 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Dec 1, 2011
Features
Pharm Exec's 2012 Pipeline Report
By Ben Comer
It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle?
RaQualia's New Spin on the Startup
By William Looney
Pharm Exec sits down with CEO Atsushi Nagahisa to explore how culture can maximize the value of an inherited portfolio
The Medicines Adherence Challenge
By William Looney
Keeping skittish patients on their medicines ought to be a strategic priority for Big Pharma — but is it? Pharm Exec convenes an expert round table to examine how best to make progress and agree on some practical steps for incorporation in the campaign agenda.
Country Report
UK Report: Keep Calm and Carry On ... Differently
By Sponsored by Focus Reports
Even as the global economic roller coaster affects one of the country's dearest public institutions—the National Health Service—there is still reason for optimism in these times of austerity
Column
Europe's Transparency Directive Revisited
By Reflector
The effect on pharma of the EU's Transparency Directive has been overly constraining, but will the mooted revisions offer any room to maneuver?
Give It to Me Straight!
By Ben Comer
Patients want to take a more active role in treatment decisions. Drug facts boxes in DTC ads represent a crucial element of informed consent.
Artists & Ad Men
By Ben Comer
Some of the most creative and influential graphic designers and illustrators did time in pharma marketing.
China's Future in Bioscience
By George Baeder
Will big investments in infrastructure carry the day in positioning China as a global drug innovation powerhouse?
The Payoff for Payers
By Lujing Wang
Thorough risk assessment is essential before placing bets on good evidence that clears a path to approval.
FDA Gets a New Look
By Jill Wechsler
Agency expansion and globalization promote innovation, collaboration, and organizational changes
From the Editor
Was 2011 the End of the Beginning?
By William Looney
The gap in perception is one of industry's biggest problems because it adds ballast to the idea that medicines are just a simple procurement item, writes William Looney.

ADVERTISEMENT

Click here